MYGN vs PSA · rev $837.6M vs rev $1.23B
Myriad Genetics Inc (MYGN) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
Latest reported PSA revenue for 2026-06-30 was $1.23B. Net income was $500.0M. Revenue was up 1.2% from 2026-03-31 to 2026-06-30. PSA currently screens at market cap $0.
MYGN currently screens at market cap $413.7M. PSA currently screens at market cap $0.
Not investment advice. Open the MYGN and PSA stock pages for the full models.
Not investment advice.